俄罗斯制药工业市场前景及投资研究报告-外文版培训课件

INDUSTRIES

&

MARKETSPharmaceuticalindustryinRussiaCHAPTER

01OverviewMarketvalueofpharmaceuticalsinRussiafrom2012to2023withaforecastuntil2025(inbillionRussianrubles)PharmaceuticalmarketsizeinRussia2012-20253,5003,0002,5002,9222,7652,5732,5782,2982,0412,0001,5001,0005001,8591,6941,6401,5231,4031,26220141,1222013969020122015201620172018201920202021202220232024*2025*4/statistics/1127319/pharmaceutical-market-value-russiaTheRussianpharmaceuticalmarketreachedapproximately2.6trillionRussianrublesin2023,markinganearly0.2percentincreasefromthepreviousyear.Thevalueofpharmaceuticalsaleswasforecasttoincreaseto2.9trillionRussianrublesin2025.ReadmoreNote(s):Russia;2012to2023Source(s):Deloitte;DSMGroup;InvestinRussiaMarketsizeofthepharmaceuticalindustryinRussiafrom2017to2023withaforecastuntil2025,bysegment(inbillionRussianrubles)PharmaceuticalmarketsizeinRussia2017-2025,bysegmentCommercialmarketPublicprocurementParapharmaceuticals3,5003,0002,5002,0001,5001,0005004058843778483278943468002908322792625772404642414516321,6321,5371,43220231,35020221,1712021102020199480201720182024*2025*5Description:CommercialsalesoccupiedthelargestshareofthepharmaceuticalmarketinRussia,forecasttoexceed1.6trillionRussianrublesin2025.Thevalueofpharmaceuticalsacquiredviapublicprocurementincreasedovertheperiodunderconsideration,measuringat896billionRussianrublesin2022.ReadmoreNote(s):Russia;2017to2023;*Forecast.ReadmoreSource(s):DSMGroupMarketvolumeofthepharmaceuticalindustryinRussiafrom2020to2023,bysegment(inmillionpackages)PharmaceuticalsalesvolumeinRussia2020-2023,bysegmentCommercialsectorHospitalpurchasesHigh-costICD+EssentialDrugCoverage+RegionalDrugCoverage*7,0006,0005,0004,0003,0002,0001,000020202021202220236Description:Around4.5billionpackagesofpharmaceuticalsweresoldinthecommercialsegmentinRussiain2023.Inmonetaryterms,commercialpharmasalesreachedapproximately1.4trillionRussianrublesinthatyear.Thevolumeofpharmaceuticalspurchasedbyhospitalsfellto455millionpackages.ReadmoreNote(s):Russia;2020to2023;*Pharmaceuticalbenefitsprograms.Thestatistichasbeencompiledfromseveralreportsbythesource.

ReadmoreSource(s):DSMGroupCommercialpharmaceuticalmarketvalueinRussiafromMarch2021toDecember2023(inbillionRussianrubles)CommercialpharmamarketvalueinRussiamonthly2021-2023200173.218016014012010080133124.2121.3116.5115.5112.1107.3105.1105.5105.3103.1100.698.689.287.983.660402007Description:ThevalueofpharmaceuticalgoodssoldinRussiahasbeenfluctuantovertheperiodunderconsideration.InDecember2023,thefigurewasapproximately154billionRussianrubles,markinganincreaseofover16percentfromthepreviousmonth.ComparedtoMarch2022,however,ꢀthemarketincreasedbyabout24percent.ReadmoreNote(s):Russia;March2021toDecember2023Source(s):DSMGroupMedicineretailsalesrevenueinRussiafrom2015to2022(intrillionRussianrubles)RetailsalesofmedicinesinRussia2015-20222.01.81.61.41.791.531.361.241.141.21.00.80.60.40.20.01.11.061.02201520162017201820192020202120228Description:In2022,retailsalesofmedicinesinRussiaamountedtoapproximately1.8trillionRussianrubles.Afteradecreasein2017,therevenueincreasedgraduallyandreacheditshighestinthelatestyearobserved.

ReadmoreNote(s):Russia;2015to2022Source(s):RussianFederalStateStatisticsServiceProductionvalueofpharmaceuticalsinRussiafrom2015to2023(inbillionRussianrubles)PharmaceuticalproductionvalueinRussia2015-2023800700600500400716.5668.7624.5534.3425.3333.6336314.53002001000254.12015201620172018201920202021202220239Description:In2023,thevalueofpharmaceuticalsproducedinRussiareachedmorethan716billionRussianrubles,whichwasthehighestfigurerecordedovertheobservedperiod.Inthepreviousyear,theannualproductionvaluewascloseto669billionRussianrubles.ReadmoreNote(s):Russia;2015to2023Source(s):RNCPharma;RussianFederalStateStatisticsServiceDistributionofpharmaceuticalsalesvolumeinRussiain2023,bypricecategoryPharmaceuticalsalesvolumeshareinRussia2023,bypricecategoryOver1,000RUB5.3%500-1,000RUB14%Upto100RUB32.8%100-500RUB47.9%10Description:In2023,overfivepercentofthepharmaceuticalsalesinpackagesinRussiawereoccupiedbymedicationwithapriceabove1,000Russianrubles.Productsthatcostlessthan100Russianrublesaccountedforapproximately33percentofthesalesinpackagesandaroundꢀfivepercentinmonetaryterms.ReadmoreNote(s):Russia;2023Source(s):DSMGroupInflationrateofpharmaceuticalproductsinRussiafrom2008to2023InflationonpharmaceuticalsinRussia2008-202318%16.2%16%14%14%12.7%12%10%8%10.3%8.8%7.5%7.3%6.1%20186%6%5%3.7%20133.7%20214%2.6%20231.8%20192%0.7%20100.3%20170%20082009201120122014201520162020202211Description:In2023,pricesofmedicinesinRussiadecreasedby2.6percentrelativeto2022.Thelevelofinflationhasdecreasedmorethanthirdcomparedtothepreviousyear,whichwasmeasuredat7.5percent.

ReadmoreNote(s):Russia;2008to2023Source(s):Deloitte;DSMGroup;InvestinRussiaWeeklyyear-on-yearsalesvaluegrowthofpharmaceuticalsinRussiafromJanuary10toMarch12,2023,bycategoryPharmaceuticalssalesvaluegrowthinRussiaweekly2023,bycategoryFinishedpharmaceuticalproductsNutritionalsupplementsPharmaceuticalcosmeticsOtherparapharmaceuticals140%120%100%80%60%40%20%0%-20%-40%-60%12Description:SalesoffinishedpharmaceuticalproductsinRussiadecreasedbynearly45percentinmonetarytermsovertheweekendingMarch12,2023,comparedtothecorrespondingweekofthepreviousyear.Thevalueofpharmaceuticalcosmeticssalesduringthesameperiodsawadecreaseofmorethan50percent.ReadmoreNote(s):Russia;January10toMarch12,2023Source(s):DSMGroupFixedcapitalinvestmentinproductionofmedicinesandmaterialsusedformedicalpurposesinRussiafrom2015to2022(inbillionRussianrubles)MedicinesandmedicalmaterialsinvestmentinRussia2015-2022120105.810082.581.18060402005340.83535.528.62015201620172018201920202021202213Description:In2022,over81billionRussianrubleswereinvestedinfixedcapitalinproductionofmedicinesandmaterialsusedformedicalpurposesinRussia,downfromaround82billionRussianrublesinthepreviousyear.Afterashortdecreasetoabout29billionRussianrublesin2016,theinvestmentvaluecontinuedtogrowinthefollowingyears,nearlydoublingbetween2019and2020.ReadmoreNote(s):Russia;2015to2022Source(s):RussianFederalStateStatisticsServiceCHAPTER

02SegmentsPharmaceuticalsalesrevenuedistributioninRussiafromJanuarytoJuly2023,bysegmentPharmaceuticalrevenueshareinRussia2023,bysegment70%63.2%60%50%40%30%20%10%19.6%12.5%5.3%0%RetailsegmentPreferentialprovisionClinicalsegmentTargetsegment15Description:TheretailsegmentwasastrongholdoftheRussianpharmaceuticalmarketfromJanuarytoJuly2023.Itcontributedtoaround63percentofthesalesrevenue.Preferentialprovisionaccountedfornearlyone-fifthofthetotal.

ReadmoreNote(s):Russia;JanuarytoJuly2023Source(s):AlphaResearch&MarketingShareofgenericandoriginalmedicationsalesinpackagesinRussiafrom2020to2023GenericandoriginalmedicationsalesvolumeshareinRussia2020-2023GenericOriginal100%13%13.6%13.1%18.3%90%80%70%60%50%40%30%20%10%0%87%86.4%202286.9%202381.7%2020202116Description:In2023,genericsoccupiedanover86-percentshareoftotalpackagesofpharmaceuticalssoldinRussia.Theshareofsalesvolumeoforiginalmedicationsinthecountryreachedꢀ13percent,markingadecreasefromthepreviousyear.

ReadmoreNote(s):Russia;2020to2023Source(s):DSMGroupDistributionofcommercialmedicinesalesrevenueinRussiafrom2020to2023,byoriginMedicinesalesvalueshareinRussia2020-2023,byoriginImportedLocallyproduced100%90%80%44.1%45.5%45.7%48.1%70%60%50%40%30%20%10%0%55.9%202054.5%202154.3%202251.9%202317/statistics/1236345/commercial-pharmacy-sales-share-by-origin-russiaIn2023,pharmaceuticalsofforeignorigincomprisedthelargestshareofRussianpharmaceuticalcommercialsalesofmedicinesinmonetaryterms,at51.9percent.Theshareofrevenuefromdomesticdrugsalesslightlyincreasedfromthepreviousyear.ReadmoreNote(s):Russia;2020to2023Source(s):DSMGroupDistributionofover-the-counter(OTC)andprescriptionmedicationsalesinpackagesinRussiafrom2020to2023MedicationsalesvolumeshareinRussia2020-2023,bytypeOTCPrescription100%90%80%70%60%50%40%30%20%10%0%36.7%38.3%38.3%39.5%63.3%202161.7%202061.7%202260.5%202318Description:In2023,over-the-counter(OTC)medicationsaccountedforapproximately61percentofpharmaceuticalsalesinpackagesinRussia.Theshareofprescriptionmedicinesmarkedaslightincreaseovertheobservedperiod.Thelargestshareofthemarketinphysicaltermswasoccupiedbymedicationinthepricecategoryfrom150to500Russianrublesperpackage.ReadmoreNote(s):Russia;2020to2023Source(s):DSMGroupRevenueoftheanalgesicsmarketinRussiafrom2018to2029(inbillionU.S.dollars)RevenueoftheanalgesicsindustryinRussia2018-20290.70.60.50.590.560.540.520.490.480.470.440.40.380.40.30.20.10.00.350.3520182019202020212022202320242025202620272028202919Description:Therevenueinthe'Analgesics'segmentoftheotcpharmaceuticalsmarketinRussiawasforecasttocontinuouslyincreasebetween2024and2029byintotal0.1billionU.S.dollars(+21.28percent).Afterthesixthconsecutiveincreasingyear,theindicatorisestimatedtoreach0.59billionU.S.dollarsandthereforeanewpeakin2029.ReadmoreNote(s):Russia;2018to2029Source(s):ConsumerMarketInsightsRevenueofthedigestives&intestinalremediesmarketinRussiafrom2018to2029(inmillionU.S.dollars)Revenueofthedigestives&intestinalremediesindustryinRussia2018-2029250205.59202.61200.45198.29196.13192.33200188.63183.3179.48176.75171.36163.3915010050020182019202020212022202320242025202620272028202920Description:Therevenueinthe'Digestives&IntestinalRemedies'segmentoftheotcpharmaceuticalsmarketinRussiawasforecasttocontinuouslyincreasebetween2024and2029byintotal14millionU.S.dollars(+7.42percent).Accordingtothisforecastin2029,theindicatorwillhaveincreasedforthesixthconsecutiveyearto202.61millionU.S.dollars.ReadmoreNote(s):Russia;2018to2029Source(s):ConsumerMarketInsightsRevenueofthecold&coughremediesmarketinRussiafrom2018to2029(inbillionU.S.dollars)Revenueofthecold&coughremediesindustryinRussia2018-20291.61.41.391.341.291.241.181.151.21.00.80.60.40.20.01.131.0610.970.930.8220182019202020212022202320242025202620272028202921Description:Therevenueinthe'Cold&CoughRemedies'segmentoftheotcpharmaceuticalsmarketinRussiawasforecasttocontinuouslyincreasebetween2024and2029byintotal0.3billionU.S.dollars(+26.55percent).Afterthesixthconsecutiveincreasingyear,theindicatorisestimatedtoreach1.39billionU.S.dollarsandthereforeanewpeakin2029.ReadmoreNote(s):Russia;2018to2029Source(s):ConsumerMarketInsightsRevenueofthevitamins&mineralsmarketinRussiafrom2018to2029(inbillionU.S.dollars)Revenueofthevitamins&mineralsindustryinRussia2018-20290.80.70.60.670.650.620.60.570.560.540.510.50.40.30.20.10.00.470.420.40.3920182019202020212022202320242025202620272028202922Description:Therevenueinthe'Vitamins&Minerals'segmentoftheotcpharmaceuticalsmarketinRussiawasforecasttocontinuouslyincreasebetween2024and2029byintotal0.1billionU.S.dollars(+18.52percent).Afterthesixthconsecutiveincreasingyear,theindicatorisestimatedtoreach0.67billionU.S.dollarsandthereforeanewpeakin2029.ReadmoreNote(s):Russia;2018to2029Source(s):ConsumerMarketInsightsRetailsalesofbiologicallyactiveadditives(BAAs)inpharmaciesinRussiafrom2019to2023(inbillionRussianrubles)BiologicallyactiveadditivesmarketvalueinRussia2019-2023140120127.6112.810080604020092.981.766.62019202020212022202323Description:Salesofbiologicallyactiveadditives(BAAs)inRussiaamountedtoover127billionRussianrublesin2023.Thefigureincreasedbyaround13percentfromthepreviousyear.TheleadingproducerofdietarysupplementsbyrevenueinthecountrywasEvalar.ReadmoreNote(s):Russia;2019to2023Source(s):DSMGroupCHAPTER

03CompaniesandbrandsLeadingpharmaceuticalcorporationsinRussiafromJanuarytoJuly2023,byrevenueshareLeadingpharmacorporationsinRussia2023,bysalesshareSalesshare2.0%0.0%Stada0.5%1.0%1.5%2.5%3.0%3.5%4.0%3.87%3.83%4.5%BayerOTCPharmServier3.21%3.2%Abbott3.17%Novartis2.83%2.8%TevaKRKA2.78%2.76%SanofiBinnopharmGroup2.49%25Description:Inthefirstsevenmonthsof2023,OTCPharmheldtheleadingpositionontheRussianpharmaceuticalmarketwithanapproximatelyfour-percentshareofthetotalrevenuefromcommercialsales.Bayerwassecondwithashareof3.8percent.

ReadmoreNote(s):Russia;JanuarytoJuly2023Source(s):AlphaResearch&MarketingLeadingproducersinthepharmaceuticalindustryinRussiain2023,bysalesrevenue(inmillionpacks)LeadingpharmaceuticalproducersinRussia2023,byrevenueSalesinbillionRussianrubles150050100200250300350PharmstandardOzon305182.2Stada176.3OTCPharmTeva166.7128.8KRKA8783.181.9SanofiServierNovartisAbbott71.670.826Description:In2023,therankingofpharmaceuticalproducersinRussiawasledbyPharmstandard,whosesalesreachedapproximately305millionpacks.ꢀTherevenueofOzonwasthesecondhighest,measuringatover182ꢀmillionpacks.Severalinternationalbrands,includingStada,Sanofi,andAbbottceasedadvertisingoperationsinRussiainresponsetoitsinvasionofUkraineinFebruary2022.ReadmoreNote(s):Russia;2023Source(s):DSMGroupRankingofpharmaceuticaldistributorsinRussiain2023,byrevenue(inbillionRussianrubles)LeadingpharmadistributorsinRussia2023,byrevenueRevenueinbillionRussianrubles150

200050100250300350335.7333.8400PulsProtekKatren314.8GrandCapitalR-Pharm156.6145.2BCC108.1PharmcomplectIrvin291.980.472.3PharmimexLancet53.727Description:In2023,Pulsearnedalmost336billionRussianrubles,listingfirstintherankingofpharmaceuticaldistributorsacrossRussia.Protekrankedsecond,withasalesvalueofover333billionRussianrubles.ReadmoreNote(s):Russia;2023Source(s):DSMGroupLeadingmedicinebrandsinRussiain2023,bysalesvalue(inbillionRussianrubles)MostpopularmedicationsinRussia2023,bysalesvalueSalesinbillionRussianrubles1005152025XylometazolineIbuprofen2116.2RivaroxabanPancreatinApixaban14.61312.4Bisoprolol11.4Ursodiol11.2UmifenovirAdemetionineOmeprazol10.610.18.628Description:XylometazolinewasthemostpopularmedicationbrandinRussiain2023,whenitssalesreachedalmost21billionRussianrubles.ThesecondleadingmedicinewasIbuprofen,havingearned16.2billionRussianrublesinthatyear.

ReadmoreNote(s):Russia;2023Source(s):DSMGroupRankingofmasspharmaceuticalcosmeticbrandsinRussia2023,bysalesvalue(inmillionRussianrubles)MostsoldmasspharmaceuticalcosmeticbrandsinRussia2023SalesinmillionRussianrubles100

150050200250300350EVOMysunshine/МоесолнышкоBabyCream/ДетскийкремGinokomfort/ГинокомфортFloresan/ФлоресанNivea316.5281.1261.7196.2186.6172.7Ullex147.6LaboratoryKora132.6129.8Novosit29Description:With316.5millionRussianrublesinsalesvalue,EVOwastheleadingmassmarketbrandofpharmaceuticalcosmeticsinRussiain2023.Mysunshine,orМоёСолнышко,cameinthesecondplacewith281.1millionRussianrublesinsales.

ReadmoreNote(s):Russia;2023Source(s):DSMGroupRankingofpremiumpharmaceuticalcosmeticbrandsinRussiain2023,bysalesvalue(inmillionRussianrubles)MostsoldpremiumpharmaceuticalcosmeticbrandsinRussia2023SalesinmillionRussianrubles01,0002,0003,0004,0005,0005,023.26,000LaRoche-PosayVichy2,935.9BiodermaLibredermAvene2,172.61,810.61,122.1Uriage887.7TopicreamDucray362.4338.8310.3Eucerin30/statistics/1121156/russia-leading-premium-pharmaceutical-cosmetic-brandsFrenchLaRoche-Posay,abrandofL'OréalGroup,wasleadingbythesalesvolumeontheRussianpremiumpharmaceuticalmarketin2023.Vichyamountedtonearly2.9billionRussianrublesinsalesovertheobservedperiodandlistedsecondintheranking.ReadmoreNote(s):Russia;2023Source(s):DSMGroupRankingofhealingpharmaceuticalcosmeticbrandsinRussiain2023,bysalesvalue(inmillionRussianrubles)MostsoldhealingpharmaceuticalcosmeticbrandsinRussia2023SalesinmillionRussianrubles200

300

40001005006007008009001,000983.21,100Lipobase/ЛипобейзLactacyd823.9685.3672.1641.8602.6HorseForce/ЛошадинаяСилаAleranaCinovit/Циновит911YourRescueService/911ВашаСлужбаСпасенияBoroPlusSulsen/СульсенDryDry489.8438430Epigen392.131Description:LipobasewasthemostdemandedbrandinthesegmentofhealingpharmaceuticalcosmeticsinRussiain2023.LactacydandHorseForce,orЛошадинаяСила,amountedto823.9millionand685.3millionRussianrublesinsalesoverthegivenperiodandlistedsecondandthirdintheranking,respectively.ReadmoreNote(s):Russia;2023Source(s):DSMGroupLeadingbrandsofbiologicallyactiveadditivesinRussiain2023,byrevenue(inbillionRussianrubles)Highest-earningbrandsofbiologicallyactiveadditivesinRussia2023RevenueinbillionRussianrubles100246812141618EvalarSolgar15.588.2Vitamir3.65Bak-Set3.313.14DoppelherzMaxilac2.2FemibionDetrimaxImplovitVitrum2.081.91.81.632Description:BiologicallyactiveadditivesunderthedomesticbrandEvalarhadthehighestsalesinRussiain2023,atover15.58billionRussianrubles.Theproducerofthatbrand,alsonamedEvalar,wastheleadingmanufacturerofdietarysupplementsbyrevenueinRussiainthatyear.SolgarfromtheUnitedStatesrankedsecond,atapproximatelyeightbillionRussianrubles.ReadmoreNote(s):Russia;2023Source(s):DSMGroupCHAPTER

04PharmaciesNumberofpharmacyestablishmentsinRussiafrom2015to2023PharmacycountinRussia2015-202390,00080,00078,89672,59167,48270,00060,00050,00040,00030,00020,00010,000064,49563,95462,42259,44156,86255,97720152016201720182019202020212022202334Description:Russiahadnearly78,900pharmacyestablishmentsin2023,upfromroughly72,600recordedinthepreviousyear.Overtheperiodunderconsideration,thecountry'spharmacycounthascontinuouslyincreased.

ReadmoreNote(s):Russia;2015to2023Source(s):DSMGroupMarketrevenueshareofleadingpharmacychainsinRussiain2023,bycountMarketshareofleadingpharmacychainsinRussia2023,bycount70%60%50%40%63%52%32%30%22%20%10%0%Top3Top5Top10Top2035Description:In2023,theleadingthreepharmacychainsinRussiaaccountedforafifthofthemarketrevenue.Moreover,major20companiesoccupiedfurther63percentoftotalsales.

ReadmoreNote(s):Russia;2023Source(s):DSMGroupRankingofconventionalpharmacychainsinRussiain2022,bypharmaceuticalmarketshareLeadingconventionalpharmaciesinRussia2022,bymarketsharePharmaceuticalmarketshare2%

3%0%1%4%5%6%7%8%RiglaAprel7.5%6.3%Erka-PharmandMelodiyaZdorovyaPlanetaZdorovya*Neo-Pharm4.9%4.8%4%PharmacyChain36.6*Vita3.5%3.4%3.1%FarmlendMaksavit(including36.7)*Magnit*1.2%1.2%36Description:In2022,Riglaoccupieda7.5-percentshareintheRussianpharmaceuticalretailmarket,whichwasthelargestamongconventionalpharmacychainsinthecountry.AprelandErka-Pharmwerethesecondmajorpharmacychain,withamarketshareofnearlysixpercentandfivepercent,respectively.ReadmoreNote(s):Russia;2022;*Expertestimate.Referstotheshareofpharmacysalesofpharmaceuticals.ReadmoreSource(s):RNCPharmaRankingofmajorpharmaceuticalproductretailersinRussiain2023,byomnichannelperformance(inpoints)OmnichannelperformancerankingofpharmaciesinRussia2023Rankingscore051015202530ZdravCityGorzdrav27.9427.3726.8826.6325.7525.4824.9424.5124.2123.9PlanetaZdorovyaApteka36,6AprelStolichkiOzerkiMonastirevZhivikaEapteka37Description:ZdravCityrankedastheleadingomnichannelpharmaceuticalproductsretailerinRussiain2023,scoring27.94points.ItwascloselyfollowedbyGorzdrav,whichscored27.37points.ReadmoreNote(s):Russia;2023Source(s):AWG;DataInsight(RU)CHAPTER

05OnlineretailSalesrevenueofonlinepharmaciesinRussiafrom2020to2023(intrillionRussianrubles)OnlinepharmacymarketrevenueinRussia2020-20231210810.67.765.23.942.62020202021202220232024*39/statistics/1075060/e-pharmacy-market-volume-in-russiaTherevenueofonlinepharmaciesinRussiareached7.7trillionRussianrublesin2023.Thatmarkedanincreasebyapproximately48percentcomparedtothepreviousyear.Thenumberofe-pharmacyordersalsoincreased,reaching142millionin2022.ReadmoreNote(s):Russia;2020to2023;*Forecast.ꢀ

Thefiguresareprovidedforonlinepharmaciesthatmadeitinthetop1,000e-commerceinRussiabynumberoforders.Accordingtothesource,thesegment"includesonlinestoresspecializingprimarily[...]

ReadmoreSource(s):DataInsight(RU);Dostavista;IQVIA;Masterdelivery;SAP;TinkoffBankNumberofordersfromonlinepharmaciesinRussiafrom2018to2024(inmillions)OnlinepharmacyordercountinRussia2018-20249080708373.86051.651.550403028.624.917201002018201920202021202220232024*40Description:Russianconsumersmade51.5millionordersinonlinepharmaciesin2023.Thenumberofpharmaceuticalgoodspurchasesviatheinternethasincreasedsteadilyinthecountrysince2018.Thehighestnumberofordersweremadeonthee-commerceplatformApteka.ru,at46.7millionin2023.RussiawasthecountrywiththelargestshareofpeoplewhoorderedmedicationsonlineinEuropein2021,measuredat40percent.ItwasfollowedbyotherCentralandEasternEuropean[...]

ReadmoreNote(s):Russia;2018to2023;*Forecast.ꢀ

Thefiguresareprovidedforonlinepharmaciesthatmadeitinthetop1,000e-commercelistbynumberoforders.Accordingtothesource,thesegment"includesonlinestoresspecializingprimarilyinthe[...]

ReadmoreSource(s):DataInsight(RU);Dostavista;IQVIA;Masterdelivery;SAPAverageordervalueinonlinepharmaciesinRussiafrom2018to2023(inRussianrubles)OnlinepharmacyaverageordervalueinRussia2018-20235,0004,5004,0003,5003,0002,5002,0001,5001,0005004,3003,4203,1502,3001,85020221,50020230201820192020202141Description:TheaverageordervalueinRussiane-pharmacieswasmeasuredat1,500Russianrublesin2023.Theaveragespendingdecreasedcomparedtothepreviousyear.Amongleadingpharmaceuticale-commerceretailersacrossthecountry,Stolichki.ruhadthehighestaveragebillatovertwothousandRussianrublesin2023.ReadmoreNote(s):Russia;2018to2023Source(s):DataInsight(RU)GeographicaldistributionofonlinepharmaciesinRussiain2022ShareofonlinepharmaciesinRussia2022,bylocation45%39%40%35%30%25%20%15%10%5%34%18%9%0%MoscowandMoscowOblastUralandAsianpartofRussiaEuropeanpartofRussiaSaintPetersburgandLeningradOblast42Description:In2022,nearly40percentofe-pharmaciesinRussiawereregisteredinMoscowandtheMoscowOblast.Furthermore,approximatelyonethirdofonlineretailersinthatsectorwerelocatedintheUralsandtheAsianpartofRussia.

ReadmoreNote(s):Russia;2022Source(s):DataInsight(RU);ROWIFactoringPlusShareofonlinepharmaciesofferingselecteddeliverytypesinRussiain2022E-pharmacydeliverymethodsinRussia2022120%100%100%80%60%40%20%0%49%2%0%Selfpick-upfromnon-automatedaccesspoints,includingofflinepharmaciesCourierdeliveryRussianPostLocker43Description:Alloftheleadinge-pharmaciesinRussiaofferedtheirconsumerstopickupordersfromanon-automateddeliveryaccesspointin2022.Furthermore,aroundonehalfprovidedanoptiontogetmedicinesdeliveredwithacourierservice.

ReadmoreNote(s):Russia;2022Source(s):DataInsight(RU);ROWIFactoringPlusYear-over-yearrevenuegrowthofselectedonlinepharmaciesinRussiafrom2022to2023Pharmae-commercerevenuegrowthinRussia2022-2023,byplatform20222023180%164%160%140%120%100%80%60%40%20%0%79.9%55%49%31%21%YutekaEaptekaZdravcity44Description:Amongthelistedpharmaceuticale-commerceplatformsinRussia,Yutekademonstratedthefastestgrowth,havingincreaseditsrevenuebyapproximately80percentbetween2022and2023.Thee-pharmacyZdravcityrecordedarevenuegrowthof21percentoverthesameperiod.ReadmoreNote(s):Russia;2022to2023Source(s):DSMGroupCHAPTER

06TradeExportvalueofpharmaceuticalproductsfromRussiafrom2015to2022(inmillionU.S.dollars)PharmaceuticalexportvalueinRussia2015-20223,0002,5002,0001,5002,523.161,031.991,000843.82019792728.112017634.62529.752015471.822022*5000201620182020202146Description:Russiaexportedpharmaceuticalproductsworthapproximately472billionU.S.dollarsin2022,havingdecreaseditsexpor